The U.S. GLP-1 receptor agonists market was valued at USD 48.50 billion in 2025. It is estimated at USD 55.00 billion in 2026 and is projected to reach USD 122.08 billion by 2036, growing at a CAGR of 8.3% over the 2026-2036 forecast period. The report covers epidemiology and the treated population, pricing and reimbursement, FDA approvals and compounding rules, the pipeline, manufacturing and supply, prescription trends, the value chain, competition, and future growth opportunities.
The study covers branded prescription drugs sold in the U.S. that activate the glucagon-like peptide-1 receptor, either alone or together with other incretin receptors, to control blood sugar, curb appetite, and reduce body weight. Products include tirzepatide (Mounjaro and Zepbound), semaglutide (Ozempic, Wegovy, Rybelsus, and oral Wegovy), dulaglutide (Trulicity), liraglutide (Victoza and Saxenda), and next-generation incretins such as oral small molecules like orforglipron, multi-agonists like retatrutide, and amylin combinations like CagriSema. The market is valued at manufacturer net sales, and compounded or unapproved products are excluded.
According to the Centers for Disease Control and Prevention (CDC), roughly two in five U.S. adults were living with obesity during 2021-2023, and some 38 million people in the country have diabetes. The U.S. also generates roughly three-fifths of global GLP-1 sales. Leadership has shifted quickly: Eli Lilly reported 2025 Mounjaro revenue of USD 22.97 billion, up 99%, and Zepbound revenue of USD 13.54 billion, up 175%, while Novo Nordisk, which built the category with semaglutide, guided to a sales decline of 5% to 13% for 2026. At the same time, Lilly reported that lower realized prices cut its fourth-quarter 2025 revenue by about 5%, showing that volume and value are now moving at different speeds.
Falling net prices slow value growth, as Lilly expects price to reduce revenue by a low to mid teens percentage in 2026, and Medicare negotiated prices for semaglutide under the Inflation Reduction Act take effect in 2027. Many Medicaid programs and employers limit or drop obesity coverage, including North Carolina's state employee plan in 2024, and pharmacy benefit managers use formulary exclusions, such as CVS Caremark's choice of Wegovy over Zepbound from July 2025. Gastrointestinal side effects, cost, and coverage changes lead many patients to stop within a year, and compounded and counterfeit products still divert demand even after the FDA declared the shortages resolved. Further challenges include scaling peptide and pen production, open questions on long-term safety and lean mass loss, payer budget pressure, and intensifying competition that requires differentiation on efficacy, tolerability, dosing, and price.
Oral therapies are a major opportunity, as many patients prefer pills and tablets are easier to make at scale; the FDA approved oral Wegovy in December 2025, and Lilly expects approval of orforglipron in the second quarter of 2026. Multi-agonists and amylin combinations, such as retatrutide, with six Phase 3 readouts planned for 2026, and CagriSema, could command premium prices, and new indications from osteoarthritis to psoriatic arthritis are being tested. Key trends include rapid growth in cash-pay and manufacturer-direct sales, tirzepatide overtaking semaglutide, deals that trade lower prices for broader coverage, and the arrival of new entrants such as Pfizer, through its late-2025 purchase of Metsera, and Roche, through its petrelintide partnership with Zealand Pharma.
Based on molecule, the market is segmented into tirzepatide (Mounjaro and Zepbound), semaglutide (Ozempic, Wegovy, Rybelsus, and oral Wegovy), dulaglutide, liraglutide, and next-generation incretins, which include oral small molecules, multi-agonists, and amylin combinations. Tirzepatide is expected to hold the largest share in 2026, driven by the scale of Mounjaro and Zepbound, which together brought in USD 36.5 billion worldwide in 2025 according to Lilly, by their lead in new prescriptions for both diabetes and obesity, and by the weight loss advantage that supports physician preference. Next-generation incretins are projected to grow at the highest CAGR during the forecast period, as orforglipron is expected to launch and retatrutide and other multi-agonists follow later in the decade. Dulaglutide and liraglutide are older products losing ground to newer agents.
The route of administration analysis compares injectable products, delivered by pens and vials, with oral products. Injectables are expected to account for the larger share in 2026, as tirzepatide and semaglutide injections dominate prescriptions and vials are expanding cash-pay access. The oral segment is projected to record the higher CAGR, supported by oral Wegovy, cleared in December 2025, the expected orforglipron approval, patient preference for pills, and lower manufacturing complexity without injection devices.
The indication analysis covers type 2 diabetes, obesity & chronic weight management, cardiovascular risk reduction, obstructive sleep apnea, MASH, chronic kidney disease, and others. Type 2 diabetes is set to remain the leading indication in 2026, reflecting long-established insurance coverage, guideline support, and the size of the Mounjaro, Ozempic, and Trulicity franchises. Obesity & chronic weight management is projected to grow at the highest CAGR, as Medicare coverage begins in April 2026, direct-to-patient pricing reaches uninsured patients, and oral drugs widen the treated pool. Cardiovascular, sleep apnea, kidney, and liver indications strengthen the case for coverage.
Based on distribution channel, the market is segmented into retail pharmacies, mail-order & specialty pharmacies, direct-to-patient & telehealth, and hospital pharmacies. Retail pharmacies are expected to hold the largest share in 2026, since most insured patients fill GLP-1 prescriptions at local pharmacies under their pharmacy benefit. Direct-to-patient & telehealth is projected to grow at the highest CAGR, driven by manufacturer cash-pay programs with transparent pricing, the growing role of Zepbound vials in new prescriptions, and telehealth companies such as Hims & Hers and Ro that connect patients to prescribers.
Based on payer, the market is segmented into commercial insurance, Medicare, Medicaid, and self-pay. Commercial insurance is expected to account for the largest share in 2026, given employer-sponsored coverage of diabetes drugs and, in many plans, obesity medicines. Medicare is projected to register the highest CAGR, as the Part D obesity pilot starting in April 2026 brings coverage to older adults for the first time with a low capped copay. Self-pay continues to grow through cash-price programs, while Medicaid coverage varies widely by state.
The South is set to remain the largest regional market in 2026, owing to its large population and high rates of obesity and diabetes. According to CDC data, many of the 23 states with adult obesity prevalence of 35% or more in 2023 are in the South, as is the diabetes belt, and Texas and Florida alone generate large prescription volumes, although certain state employee plans there have cut back coverage of weight loss drugs. The West holds a significant share, led by California, with lower obesity rates but a large insured population and strong adoption of telehealth and direct-to-patient channels, even though California's Medi-Cal program stopped paying for weight loss use of these drugs in 2026.
The Midwest is projected to grow at the highest CAGR during the forecast period, supported by high adult obesity prevalence in many of its states, a large share of older residents who gain access through the Medicare obesity pilot, and expanding direct-to-patient access in areas with fewer specialists. Indianapolis-based Eli Lilly is headquartered in the region and is adding U.S. manufacturing capacity. The Northeast holds a moderate share, supported by high insurance coverage, dense networks of academic medical centers and obesity specialists, a large Medicare population that should benefit from negotiated semaglutide prices from 2027, and Novo Nordisk's U.S. operations in New Jersey.
The market is highly concentrated and led by Eli Lilly and Novo Nordisk. Lilly has taken the lead through tirzepatide, ranking first in new prescriptions for both obesity and type 2 diabetes, while Novo Nordisk, the semaglutide pioneer, is responding with oral Wegovy and CagriSema. Amgen, Pfizer, Roche, AstraZeneca, and Boehringer Ingelheim, along with biotech developers such as Zealand Pharma, Viking Therapeutics, Structure Therapeutics, and Altimmune, are preparing next-generation incretins, while pharmacy benefit managers, insurers, and telehealth companies shape patient access. Companies compete on weight loss and glucose results, side effect profiles, ease of dosing, label breadth, production capacity, pricing deals, formulary placement, and cash-pay sales. Lilly reported guidance for 2026 revenue of USD 80 billion to 83 billion, and the November 2025 White House agreements show how price-for-volume deals are becoming a central competitive tool.
Key companies profiled in the report include Eli Lilly and Company (U.S.), Novo Nordisk A/S (Denmark), Amgen Inc. (U.S.), Pfizer Inc. (Metsera) (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), AstraZeneca PLC (U.K.), Boehringer Ingelheim International GmbH (Germany), Zealand Pharma A/S (Denmark), Viking Therapeutics, Inc. (U.S.), Structure Therapeutics Inc. (U.S.), Altimmune, Inc. (U.S.), Hims & Hers Health, Inc. (U.S.), Ro (Roman Health Ventures Inc.) (U.S.), and CVS Health Corporation (CVS Caremark) (U.S.).
The study covers branded prescription drugs sold in the U.S. that activate the glucagon-like peptide-1 receptor, either alone or together with other incretin receptors, to control blood sugar, curb appetite, and reduce body weight. Products include tirzepatide (Mounjaro and Zepbound), semaglutide (Ozempic, Wegovy, Rybelsus, and oral Wegovy), dulaglutide (Trulicity), liraglutide (Victoza and Saxenda), and next-generation incretins such as oral small molecules like orforglipron, multi-agonists like retatrutide, and amylin combinations like CagriSema. The market is valued at manufacturer net sales, and compounded or unapproved products are excluded.
According to the Centers for Disease Control and Prevention (CDC), roughly two in five U.S. adults were living with obesity during 2021-2023, and some 38 million people in the country have diabetes. The U.S. also generates roughly three-fifths of global GLP-1 sales. Leadership has shifted quickly: Eli Lilly reported 2025 Mounjaro revenue of USD 22.97 billion, up 99%, and Zepbound revenue of USD 13.54 billion, up 175%, while Novo Nordisk, which built the category with semaglutide, guided to a sales decline of 5% to 13% for 2026. At the same time, Lilly reported that lower realized prices cut its fourth-quarter 2025 revenue by about 5%, showing that volume and value are now moving at different speeds.
Market Dynamics
The large number of adults with obesity or type 2 diabetes, together well over 100 million people, is the core driver, and clinical guidelines now recommend GLP-1 therapy for type 2 diabetes, especially with heart or kidney disease, and for chronic weight management. Outcome trials keep adding approved uses, including Wegovy's March 2024 approval for cardiovascular risk reduction, Zepbound's December 2024 approval for obstructive sleep apnea, Ozempic's January 2025 approval in chronic kidney disease, and Wegovy's 2025 approval for MASH. Access is also widening. Under November 2025 White House deals with Lilly and Novo Nordisk, a Part D pilot opens Medicare coverage of obesity drugs from 1 April 2026, with patient copays limited to USD 50 a month, according to the agreements, and Lilly reported that vials bought through its direct-to-patient channel accounted for close to half of new Zepbound starts in the last quarter of 2025.Falling net prices slow value growth, as Lilly expects price to reduce revenue by a low to mid teens percentage in 2026, and Medicare negotiated prices for semaglutide under the Inflation Reduction Act take effect in 2027. Many Medicaid programs and employers limit or drop obesity coverage, including North Carolina's state employee plan in 2024, and pharmacy benefit managers use formulary exclusions, such as CVS Caremark's choice of Wegovy over Zepbound from July 2025. Gastrointestinal side effects, cost, and coverage changes lead many patients to stop within a year, and compounded and counterfeit products still divert demand even after the FDA declared the shortages resolved. Further challenges include scaling peptide and pen production, open questions on long-term safety and lean mass loss, payer budget pressure, and intensifying competition that requires differentiation on efficacy, tolerability, dosing, and price.
Oral therapies are a major opportunity, as many patients prefer pills and tablets are easier to make at scale; the FDA approved oral Wegovy in December 2025, and Lilly expects approval of orforglipron in the second quarter of 2026. Multi-agonists and amylin combinations, such as retatrutide, with six Phase 3 readouts planned for 2026, and CagriSema, could command premium prices, and new indications from osteoarthritis to psoriatic arthritis are being tested. Key trends include rapid growth in cash-pay and manufacturer-direct sales, tirzepatide overtaking semaglutide, deals that trade lower prices for broader coverage, and the arrival of new entrants such as Pfizer, through its late-2025 purchase of Metsera, and Roche, through its petrelintide partnership with Zealand Pharma.
Segment Analysis
The report analyzes the market by molecule, route of administration, indication, distribution channel, payer, and region, helping stakeholders understand where volume, value, and access are changing.Based on molecule, the market is segmented into tirzepatide (Mounjaro and Zepbound), semaglutide (Ozempic, Wegovy, Rybelsus, and oral Wegovy), dulaglutide, liraglutide, and next-generation incretins, which include oral small molecules, multi-agonists, and amylin combinations. Tirzepatide is expected to hold the largest share in 2026, driven by the scale of Mounjaro and Zepbound, which together brought in USD 36.5 billion worldwide in 2025 according to Lilly, by their lead in new prescriptions for both diabetes and obesity, and by the weight loss advantage that supports physician preference. Next-generation incretins are projected to grow at the highest CAGR during the forecast period, as orforglipron is expected to launch and retatrutide and other multi-agonists follow later in the decade. Dulaglutide and liraglutide are older products losing ground to newer agents.
The route of administration analysis compares injectable products, delivered by pens and vials, with oral products. Injectables are expected to account for the larger share in 2026, as tirzepatide and semaglutide injections dominate prescriptions and vials are expanding cash-pay access. The oral segment is projected to record the higher CAGR, supported by oral Wegovy, cleared in December 2025, the expected orforglipron approval, patient preference for pills, and lower manufacturing complexity without injection devices.
The indication analysis covers type 2 diabetes, obesity & chronic weight management, cardiovascular risk reduction, obstructive sleep apnea, MASH, chronic kidney disease, and others. Type 2 diabetes is set to remain the leading indication in 2026, reflecting long-established insurance coverage, guideline support, and the size of the Mounjaro, Ozempic, and Trulicity franchises. Obesity & chronic weight management is projected to grow at the highest CAGR, as Medicare coverage begins in April 2026, direct-to-patient pricing reaches uninsured patients, and oral drugs widen the treated pool. Cardiovascular, sleep apnea, kidney, and liver indications strengthen the case for coverage.
Based on distribution channel, the market is segmented into retail pharmacies, mail-order & specialty pharmacies, direct-to-patient & telehealth, and hospital pharmacies. Retail pharmacies are expected to hold the largest share in 2026, since most insured patients fill GLP-1 prescriptions at local pharmacies under their pharmacy benefit. Direct-to-patient & telehealth is projected to grow at the highest CAGR, driven by manufacturer cash-pay programs with transparent pricing, the growing role of Zepbound vials in new prescriptions, and telehealth companies such as Hims & Hers and Ro that connect patients to prescribers.
Based on payer, the market is segmented into commercial insurance, Medicare, Medicaid, and self-pay. Commercial insurance is expected to account for the largest share in 2026, given employer-sponsored coverage of diabetes drugs and, in many plans, obesity medicines. Medicare is projected to register the highest CAGR, as the Part D obesity pilot starting in April 2026 brings coverage to older adults for the first time with a low capped copay. Self-pay continues to grow through cash-price programs, while Medicaid coverage varies widely by state.
Regional Analysis
The report covers four U.S. regions: the South, the Midwest, the West, and the Northeast. The analysis considers population, disease prevalence, age and Medicare enrollment, insurance coverage, specialist access, and use of telehealth and cash-pay channels.The South is set to remain the largest regional market in 2026, owing to its large population and high rates of obesity and diabetes. According to CDC data, many of the 23 states with adult obesity prevalence of 35% or more in 2023 are in the South, as is the diabetes belt, and Texas and Florida alone generate large prescription volumes, although certain state employee plans there have cut back coverage of weight loss drugs. The West holds a significant share, led by California, with lower obesity rates but a large insured population and strong adoption of telehealth and direct-to-patient channels, even though California's Medi-Cal program stopped paying for weight loss use of these drugs in 2026.
The Midwest is projected to grow at the highest CAGR during the forecast period, supported by high adult obesity prevalence in many of its states, a large share of older residents who gain access through the Medicare obesity pilot, and expanding direct-to-patient access in areas with fewer specialists. Indianapolis-based Eli Lilly is headquartered in the region and is adding U.S. manufacturing capacity. The Northeast holds a moderate share, supported by high insurance coverage, dense networks of academic medical centers and obesity specialists, a large Medicare population that should benefit from negotiated semaglutide prices from 2027, and Novo Nordisk's U.S. operations in New Jersey.
Competitive Landscape
The report provides a detailed review of the competitive landscape, covering key growth strategies, competitive benchmarking, a competitive dashboard that groups companies into industry leaders, market differentiators, vanguards, and emerging companies, and a 2025 market share/rank analysis. Company profiles of market leaders, pipeline developers, and access and distribution companies include business and financial overviews, product portfolios, strategic developments, and SWOT analysis.The market is highly concentrated and led by Eli Lilly and Novo Nordisk. Lilly has taken the lead through tirzepatide, ranking first in new prescriptions for both obesity and type 2 diabetes, while Novo Nordisk, the semaglutide pioneer, is responding with oral Wegovy and CagriSema. Amgen, Pfizer, Roche, AstraZeneca, and Boehringer Ingelheim, along with biotech developers such as Zealand Pharma, Viking Therapeutics, Structure Therapeutics, and Altimmune, are preparing next-generation incretins, while pharmacy benefit managers, insurers, and telehealth companies shape patient access. Companies compete on weight loss and glucose results, side effect profiles, ease of dosing, label breadth, production capacity, pricing deals, formulary placement, and cash-pay sales. Lilly reported guidance for 2026 revenue of USD 80 billion to 83 billion, and the November 2025 White House agreements show how price-for-volume deals are becoming a central competitive tool.
Key companies profiled in the report include Eli Lilly and Company (U.S.), Novo Nordisk A/S (Denmark), Amgen Inc. (U.S.), Pfizer Inc. (Metsera) (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), AstraZeneca PLC (U.K.), Boehringer Ingelheim International GmbH (Germany), Zealand Pharma A/S (Denmark), Viking Therapeutics, Inc. (U.S.), Structure Therapeutics Inc. (U.S.), Altimmune, Inc. (U.S.), Hims & Hers Health, Inc. (U.S.), Ro (Roman Health Ventures Inc.) (U.S.), and CVS Health Corporation (CVS Caremark) (U.S.).
How This Report Helps
- Provides reliable market size estimates and long-term forecasts for the U.S. GLP-1 receptor agonists market through 2036.
- Explains how disease prevalence, new indications, Medicare coverage, and direct-to-patient sales are expanding the treated population.
- Assesses the effect of falling net prices, negotiated Medicare prices, coverage gaps, and discontinuation on market value.
- Identifies high-growth opportunities across molecule, route of administration, indication, distribution channel, payer, and region.
- Tracks oral GLP-1 drugs, multi-agonists, amylin combinations, and other pipeline candidates.
- Benchmarks manufacturers, pipeline developers, and access and distribution companies on portfolios, pipelines, and strategies.
- Supports portfolio, pricing, market access, channel, partnership, and investment decisions for drug makers, payers, pharmacies, telehealth providers, and investors.
Key Questions Answered
- How large is the U.S. GLP-1 receptor agonists market today, and how will it grow through 2036?
- How will Medicare Part D obesity coverage and the November 2025 government agreements change patient volumes and prices?
- What are the main drivers, restraints, opportunities, challenges, and trends shaping the market?
- How quickly will oral GLP-1 drugs and next-generation multi-agonists gain adoption?
- Which molecule, route, indication, distribution channel, and payer segments will grow the fastest?
- How are direct-to-patient and cash-pay channels changing how patients obtain GLP-1 therapies?
- Which U.S. regions offer the most attractive growth opportunities?
- Who are the leading companies in the market, and how is the balance between Eli Lilly and Novo Nordisk shifting?
- What approvals, acquisitions, partnerships, and pricing agreements are shaping the competitive landscape?
Table of Contents
1. Introduction
2. Research Methodology
4. Market Overview
5. U.S. GLP-1 Receptor Agonists Market, by Molecule
6. U.S. GLP-1 Receptor Agonists Market, by Route of Administration
7. U.S. GLP-1 Receptor Agonists Market, by Indication
8. U.S. GLP-1 Receptor Agonists Market, by Distribution Channel
9. U.S. GLP-1 Receptor Agonists Market, by Payer
10. U.S. GLP-1 Receptor Agonists Market, by Region
11. Competitive Landscape
12. Company Profiles
13. Appendix
LIST OF TABLES
LIST OF FIGURES
Companies Mentioned
- Eli Lilly and Company
- Novo Nordisk A/S
- Amgen Inc.
- Pfizer Inc.
- F. Hoffmann-La Roche Ltd
- AstraZeneca PLC
- Boehringer Ingelheim International GmbH
- Zealand Pharma A/S
- Viking Therapeutics, Inc.
- Structure Therapeutics Inc.
- Altimmune, Inc.
- Hims & Hers Health, Inc.
- Ro
- CVS Health Corporation
